Literature DB >> 19572042

Immune globulin subcutaneous (human) vivaglobin: for the treatment of primary immunodeficiency diseases.

.   

Abstract

Entities:  

Year:  2009        PMID： 19572042      PMCID： PMC2697913     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  25 in total

Review 1.  Primary immunodeficiency diseases in adulthood.

Authors:  D S Riminton; S Limaye
Journal:  Intern Med J       Date:  2004-06       Impact factor: 2.048

2.  Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion.

Authors:  A Gardulf; L Hammarström; C I Smith
Journal:  Lancet       Date:  1991-07-20       Impact factor: 79.321

3.  IVIG adverse reactions: potential role of cytokines and vasoactive substances.

Authors:  A Bagdasarian; S Tonetta; W Harel; R Mamidi; Y Uemura
Journal:  Vox Sang       Date:  1998       Impact factor: 2.144

Review 4.  Primary immunodeficiency diseases. Report of a WHO scientific group.

Authors: 
Journal:  Clin Exp Immunol       Date:  1997-08       Impact factor: 4.330

5.  Home treatment in patients with antibody deficiency by slow subcutaneous infusion of gammaglobulin.

Authors:  J J Roord; J W van der Meer; W Kuis; G E de Windt; B J Zegers; R van Furth; J W Stoop
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

6.  Immunoglobulin replacement therapy by slow subcutaneous infusion.

Authors:  M Berger; T R Cupps; A S Fauci
Journal:  Ann Intern Med       Date:  1980-07       Impact factor: 25.391

7.  High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events.

Authors:  M C Dalakas
Journal:  Neurology       Date:  1994-02       Impact factor: 9.910

Review 8.  Primary immunodeficiencies.

Authors:  Megan A Cooper; Thomas L Pommering; Katalin Korányi
Journal:  Am Fam Physician       Date:  2003-11-15       Impact factor: 3.292

Review 9.  Risks associated with the use of intravenous immunoglobulin.

Authors:  L Ross Pierce; Nisha Jain
Journal:  Transfus Med Rev       Date:  2003-10

10.  High-dose immunoglobulin replacement therapy by slow subcutaneous infusion during pregnancy.

Authors:  M Berger; T R Cupps; A S Fauci
Journal:  JAMA       Date:  1982-05-28       Impact factor: 56.272
View more
  1 in total

1.  Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.

Authors:  H B Niebur; C M Duff; G F Shear; D Nguyen; T K Alberdi; M J Dorsey; J W Sleasman
Journal:  Clin Exp Immunol       Date:  2015-07-07       Impact factor: 4.330
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.